2026 жылында Түркияда торшалармен емдеу арқылы көздің тор қабығы ауруларын емдеуге бойынша ең жақсы бағалар мен клиникалар туралы біліңіз

Stem-cell therapy for the retina works by introducing mesenchymal stem cells (MSCs) to protect surviving neurons and improve vision. Surgeons typically use autologous cells harvested from the patient's own fat or blood, injecting them sub-retinally to release growth factors that halt progressive vision loss.

• Cell harvesting: Surgeons extract autologous stem cells from the patient's own adipose tissue or blood.
• Biological factory: Injected cells release neuroprotective proteins and anti-inflammatory molecules to rescue damaged tissue.
• Injection methods: Doctors deliver cells via sub-retinal or intravitreal injections to target specific layers.
• Treatment goal: Therapy aims to slow degeneration and enhance light sensitivity rather than full regeneration.

Bookimed Expert Insight: Data from top Istanbul clinics shows a shift toward multi-day specialized stays. While some centers offer quick injections, the most established facilities, like Dunyagoz Eye Hospital, include a 2-day hospitalization. This allows for critical post-operative monitoring that single-day outpatient clinics often bypass.

Patient Consensus: Many patients notice improved color brightness or peripheral vision within 3–6 months. However, they emphasize the importance of verifying surgeon case logs and managing expectations for advanced conditions.

Stem-cell therapy in Turkey primarily treats degenerative retinal diseases including Retinitis Pigmentosa, dry Age-Related Macular Degeneration (AMD), and Stargardt disease. Clinics utilize mesenchymal stem cells, often umbilical-cord derived, delivered via minimally-invasive intravitreal or suprachoroidal injections to potentially slow vision loss.

• Target conditions: Treats Retinitis Pigmentosa, dry macular degeneration, and hereditary Stargardt disease.
• Cell sources: Uses Wharton's jelly-derived mesenchymal cells or autologous bone marrow CD34+ cells.
• Delivery methods: Injections are performed intravitreally or into the suprachoroidal space.
• Regulatory status: Procedures require Turkish Ministry of Health approval for experimental application.

Bookimed Expert Insight: Data from Dunyagoz Eye Hospital shows that successful protocols often involve a 2-day hospital stay for monitoring. While US prices average $45,000, Turkish packages like those from Dr. Fevzi Akkan include VIP transfers and specialized ophthalmology consultations. Patients should plan for potential follow-up trips as some protocols suggest multiple sessions for stability.

Patient Consensus: Many patients report modest improvements in peripheral or color vision, though results vary significantly. Most emphasize the importance of getting pre-and-post OCT scans to objectively track the treatment impact over 12 months.

Suitable candidates for retinal stem cell therapy in Turkey typically include patients with early-to-moderate vision loss from macular degeneration, retinitis pigmentosa, or diabetic retinopathy. Success requires functional retinal tissue and intact photoreceptors to allow for effective cell integration and measurable vision improvement.

• Ocular condition: Patients with progressive retinal degeneration show better responses than stable cases.
• Retinal health: Sufficient structural integrity must exist; severely atrophied retinas rarely benefit.
• Systemic health: Candidates must have controlled blood pressure and blood sugar levels.
• Vision stage: Those with moderate impairment report higher satisfaction than those with total blindness.

Bookimed Expert Insight: Data suggests prioritizing clinics like Dunyagoz Eye Hospital, which serves 66,000 patients annually and performed Turkey's first bionic eye surgery. Specialized surgeons such as Associate Professor Muhammet Derda Ozer have performed over 25,000 procedures. Selecting a high-volume center ensures access to advanced diagnostic imaging required to verify if your retinal structure can actually support stem cell integration.

Patient Consensus: Many patients emphasize that having realistic expectations is vital, as vision improvements often range between 10% and 30%. They strongly recommend getting a detailed pre-screening from a local specialist to confirm retinal stability before traveling to Istanbul.

Stem cell therapy for the retina in Turkey is a minimally invasive procedure performed under local or topical anesthesia to ensure a painless experience. While generally safe, it remains an experimental treatment where rare risks like retinal detachment, infection, or immune reactions require careful screening by specialized ophthalmologists.

• Anesthesia: Local or topical drops typically eliminate pain during the intravitreal injection process.
• Recovery period: Patients often experience temporary blurry vision and eye irritation for several weeks.
• Hospital stay: Most protocols in Istanbul clinics include a 2-day stay for monitoring.
• Visual risks: Rare but serious complications include permanent vision loss or theoretical retinal detachment.
• Safety standards: Clinics like Liv Hospital maintain JCI accreditation to ensure rigorous infection control.

Bookimed Expert Insight: Data shows that Turkey’s leading eye centers, such as Dunyagoz, manage massive volumes of over 60,000 patients annually. This high frequency allows surgeons like Muhammet Derda Ozer, who has performed 25,000+ surgeries, to refine injection precision. For patients, this volume often translates to more predictable safety outcomes compared to lower-volume boutique clinics.

Patient Consensus: Patients report that the injection is usually painless, though the primary discomfort is persistent blurred vision after the procedure. Many advise others to verify a clinic’s specific peer-reviewed data since vision improvements are not clinically guaranteed.

Patients typically notice subjective changes like improved light sensitivity or expanded visual fields within 2 to 6 weeks. Measurable vision improvements generally require 3 to 6 months to materialize. Most Turkish ophthalmology centers focus on stabilizing retinal degeneration rather than full vision restoration.

• Early changes: Patients often report mood and sleep improvements within 2 to 4 weeks.
• Physical response: Subjective visual field changes typically appear between 2 and 6 weeks post-injection.
• Measurable results: Clinical vision testing usually shows significant improvements after 3 to 6 months.
• Long-term outcome: Stabilization and prevention of further vision loss are the most common results reported.

Bookimed Expert Insight: Data from Dunyagoz Eye Hospital shows that centers performing over 60,000 annual procedures prioritize early-stage cases for better outcomes. While marketing emphasizes recovery, the most consistent data point is successful stabilization of existing vision levels. Patients with secondary macular edema often see faster, clearer results than those with advanced photoreceptor loss.

Patient Consensus: Many patients find that initial results are incomplete, often requiring repeat procedures after 6 to 12 months. Those with earlier-stage disease report higher satisfaction than patients seeking treatment for end-stage retinal degeneration.

Turkish clinics specializing in retinal stem-cell therapy include Dunyagoz Eye Hospital Group, Memorial Health Group, and Medipol Mega University Hospital. These centers utilize mesenchymal stem cells through suprachoroidal or sub-Tenon injections to treat retinitis pigmentosa and macular degeneration under strict national protocols and JCI-accredited standards.

• Dunyagoz Etiler: Treats 66,000 patients annually using advanced protocols for degenerative retinal diseases.
• Specialist expertise: Associate Professor Muhammet Derda Ozer has performed over 25,000 ophthalmic surgeries.
• Clinical research: Medipol Mega University Hospital operates a dedicated regenerative medicine center for studies.
• Accreditation standards: Lead centers hold JCI and Turkish Medical Association certifications for patient safety.

Bookimed Expert Insight: While many clinics offer stem-cell injections, Dunyagoz Etiler and Altunizade stand out due to their massive patient volume of over 60,000 cases per year. This high frequency often correlates with more refined injection techniques. Patients should prioritize clinics like these that also offer bionic eye surgery, as it indicates a higher level of retinal technological infrastructure than standard clinics.

Patient Consensus: Patients emphasize the importance of verifying that retinal programs are listed in international registries. Many advise focusing on large university hospitals in Istanbul rather than smaller clinics to ensure better access to regulated experimental protocols.

A medical tourism package for stem cell therapy typically bundles the clinical procedure, specialist consultations, and essential logistics like airport-to-clinic transfers. These comprehensive plans often include a short hospital stay, local coordination services, and sometimes accommodations to ensure a seamless international patient experience.

• Medical services: Packages cover stem cell injections, ophthalmologist consultations, and pre-operative imaging.
• Hospital stay: Most plans include 2 days of hospitalization in an individual private chamber.
• Logistics: Providers standardly include private VIP transfers between the airport, clinic, and hotel.
• Support: Multilingual patient coordinators or 24/7 interpreters manage paperwork and clinical communication.

Bookimed Expert Insight: While many think all-inclusive means everything, Turkey's premium eye clinics often separate hotel costs. For example, Dunyagoz Eye Hospital Istanbul Etiler excludes hotels but provides a private hospital room. Always check if the 2-day stay is in-hospital or requires a separate room booking.

Patient Consensus: Patients recommend budgeting 20% extra for home-country follow-ups and travel insurance. They often highlight the value of 24/7 interpreters for navigating complex medical paperwork without stress.

Stem cell therapy for the retina in Turkey is a safe, locally approved option for patients with limited alternatives. While considered experimental by global standards, JCI-accredited facilities use GMP-certified labs for autologous treatments. Clinics operate under strict government permits for international retinal care.

• Accreditation status: Leading clinics like Liv Hospital and Dunyagoz hold JCI or ISO quality certifications.
• Government approval: Facilities possess specific Turkish government certificates to treat international ophthalmic patients legally.
• Specialist expertise: Surgeons such as Dr Muhammet Derda Ozer have performed 26,000+ eye procedures.
• Clinical protocols: Doctors typically use autologous cells from the patient's own bone marrow or tissue.

Bookimed Expert Insight: Istanbul has become a high-volume hub for these treatments. The Dunyagoz network alone serves 66,000+ patients annually. Their packages often include a 2-day hospital stay. This stay is longer than the standard outpatient care seen elsewhere.

Patient Consensus: Patients see treatment in Turkey as an experimental path for conditions like Retinitis Pigmentosa. They suggest checking the exact cell types used. Patients also recommend requesting published safety data before booking travel.

Stem cell therapy in Turkey targets degenerative retinal conditions. These include Retinitis Pigmentosa, Age-Related Macular Degeneration, and Stargardt disease. Specialist clinics in Istanbul use mesenchymal stem cells via intravitreal injections to repair tissues. Procedures typically cost $10,000 to $16,000. This offers 71% savings compared to Australian averages.

• Retinitis Pigmentosa: Addresses hereditary vision loss through progressive tissue repair.
• Macular Degeneration: Targets both wet and dry forms for vision stabilisation.
• Stargardt Disease: Manages genetic macular dystrophy using regenerative cell techniques.
• Optic Nerve Atrophy: Clinical trials in Turkey explore cellular restoration for damaged nerves.

Bookimed Expert Insight: Many providers market broad retina care. However, the Dunyagoz network serves 66,000+ patients annually and maintains specific ocular oncology units. Choosing a dedicated eye hospital ensures access to surgeons like Dr Muhammet Derda Ozer. He has performed 25,000+ procedures.

Patient Consensus: Patients find Retinitis Pigmentosa the most treated condition in Turkey. They value these options when local Australian treatments are limited. Most aim for stabilising vision. They appreciate clinics providing clear eligibility criteria for various inherited retinal dystrophies.

Stem cell therapy for the retina in Turkey involves injecting regenerative cells into or behind the eye. It is used to treat conditions like retinitis pigmentosa. Specialist clinics in Istanbul use intravitreal or retrobulbar injections. They deliver autologous stem cells typically sourced from the patient's own fat tissue.

• Delivery method: Specialists use intravitreal injections to deliver cells into the eye vitreous.
• Lab standards: Procedures occur in GMP-standard laboratories to concentrate regenerative cells and growth factors.
• Specialist expertise: Surgeons like Dr. Muhammet Derda Ozer have performed 25,000+ ophthalmic procedures.
• Hospital stay: Treatment packages at Dunyagoz Eye Hospital typically include a 2-day hospital stay.

Bookimed Expert Insight: This is often thought of as a quick outpatient visit. However, Dunyagoz Eye Hospital packages include 2 days of hospitalisation. This time allows specialists to monitor for immediate reactions after the injection. This is a significant safety advantage over clinics offering same-day discharge.

Patient Consensus: Patients often highlight the convenience of all-inclusive packages in Turkey. These bundle specialist consultations with hospital stays and airport transfers. They appreciate clear communication about treatment goals for degenerative retinal conditions.

Expected success rates for retinal stem cell therapy in Turkey typically range from 49% to 85%. Recent data shows nearly 49% of retinitis pigmentosa patients experience better visual acuity. Leading Istanbul clinics like Dunyagoz treat 66,000+ patients annually using JCI-accredited protocols.

• Clinical improvement: Reports show 75–85% efficacy in improving vision for degenerative retinal conditions.
• Visual acuity gains: Patients with macular dystrophy often see improvements of 9–19 letters.
• Retinitis pigmentosa data: About 49% of patients show measurable vision improvement within 6 months.
• Hereditary blindness: Current success rates for genetic conditions generally do not exceed 70%.

Bookimed Expert Insight: While general success rates look promising, patients should look for experienced surgeons. Dr. Muhammet Derda Ozer has performed 25,000+ procedures. He completed a vitreo-retina fellowship at the University of Kansas Medical School. This training at a major US academic centre often means higher precision in sub-retinal injections.

Patient Consensus: Outcome reality in Turkey is described as highly individual. Success often means stabilising vision rather than a full cure. Patients suggest asking clinics for specific trial data rather than relying on general percentages.